Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics

Li, Chunyao; Xiong, Dandan; Huang, Chun-Qin; He, Rong‐Quan; Liang, Hai‐Wei; Pan, Denghua; Wang, Hanlin; Wang, Yiwen; Zhu, Huawei; Chen, Gang

doi:10.12659/msm.900030

Cited by 30 publications

(23 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the let-7b miRNA gene was involved in the epithelial-to-mesenchymal transition process and cell growth in BC cells concerning Al-Harbi et al's report [26]. Li et al [27] evaluated the clinical value of miR-101-2 for the prognosis and diagnosis of BC and concluded that downexpression of miR-101-2 could be 13 Disease Markers utilized as a diagnostic marker, previously validated by a 1064-case-control study in 2014 [28]. miR-22 has been reported to play a dual role in the prognosis and recurrence of BC [23,29,30].…”

Section: Discussionmentioning

confidence: 94%

Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer

Tang

Zeng³

et al. 2019

Disease Markers

View full text Add to dashboard Cite

To identify the novel, noninvasive biomarkers to assess the outcome and prognosis of breast cancer (BC), patients with high sensitivity and specificity are greatly desired. Herein, the miRNA expression profile and matched clinical features of BC patients were extracted from The Cancer Genome Atlas (TCGA) database. The preliminary candidates were screened out by the univariate Cox regression test. Then, with the help of LASSO Cox regression analysis, the hsa-let-7b, hsa-mir-101-2, hsa-mir-135a-2, hsa-mir-22, hsa-mir-30a, hsa-mir-31, hsa-mir-3130-1, hsa-mir-320b-1, hsa-mir-3678, hsa-mir-4662a, hsa-mir-4772, hsa-mir-493, hsa-mir-556, hsa-mir-652, hsa-mir-6733, hsa-mir-874, and hsa-mir-9-3 were selected to construct the overall survival (OS) predicting signature, while the hsa-mir-130a, hsa-mir-204, hsa-mir-217, hsa-mir-223, hsa-mir-24-2, hsa-mir-29b-1, hsa-mir-363, hsa-mir-5001, hsa-mir-514a-1, hsa-mir-624, hsa-mir-639, hsa-mir-659, and hsa-mir-6892 were adopted to establish the recurrence-free survival (RFS) predicting signature. Referring to the median risk scores generated by the OS and RFS formulas, respectively, subgroup patients with high risk were strongly related to a poor OS and RFS revealed by Kaplan-Meier (K-M) plots. Meanwhile, receiver operating curve (ROC) analysis validated the accuracy and stability of these two signatures. When stratified by clinical features, such as tumor stage, age, and molecular subtypes, we found that the miRNA-based OS and RFS classifiers were still significant in predicting OS/RFS and showed the best predictive values than any other features. Besides, functional prediction analyses showed that these targeted genes of the enrolled miRNAs were enriched in cancer-associated pathways, such as MAPK/RTK, Ras, and PI3K-Akt signaling pathways. In summary, our observations demonstrate that the novel miRNA-based OS and RFS signatures are independent prognostic indicators for BC patients and worthy to be validated by further prospective studies.

show abstract

Section: Discussionmentioning

confidence: 94%

Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer

Tang

Zeng³

et al. 2019

Disease Markers

View full text Add to dashboard Cite

show abstract

“…The same study looked at putative miR-101-3p target genes were analyzed and the most predominant functions were transcription, metabolism, biosynthesis, proliferation, and transcription factor binding. This result indicated that candidate genes have a de nitive impact on the pathogenesis of BC (43).…”

Section: Discussionmentioning

confidence: 88%

“…and miR-144-3p that showed a 1.9-and 1.7-fold change up-regulation, respectively. MiR-101-3p has been shown to be dysregulated in several malignancies (42), including breast cancer (42,43). However, it has been noted discrepancies on the direction of the dysregulation.…”

Section: Discussionmentioning

confidence: 99%

“…This due to the fact that mature miR-101-3p originates from two different precursors located at different chromosomes. One precursor may be processed to 1 or 2 miRNAs and thus, the mature and precursor miRNA levels might not correlate, and this therefore will in uence the clinical interpretation (43). The same study looked at putative miR-101-3p target genes were analyzed and the most predominant functions were transcription, metabolism, biosynthesis, proliferation, and transcription factor binding.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNAs in Early Breast Cancer Patients and Its Association With Lymph Node Metastases

Escuín

López‐Vilaró

Bell

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: In recent years, miRNAs have emerged as important regulators of many cellular processes, including the various steps of the metastatic process. In addition, circulating miRNAs appear to be surprisingly stable in peripheral blood making them ideal noninvasive biomarkers for disease diagnosis. Here, we investigated the expression profile of circulating miRNAs and their association with the metastatic lymph node status in early breast cancer patients. Methods: We designed a proof-of-principle study using 16 plasma samples from patients with known sentinel lymph node status (n=12 positive and n=4 negative). We performed RNA-sequencing and validated the results by qPCR. Gene Ontology term enrichment and KEGG pathway analyses were carried out using DAVID tools.Results: We found16 differentially expressed miRNAs after adjusting for false discovery correction (q < 0.01) in patients with positive samples. Thirteen miRNAs were down-regulated (miR-339-5p, miR-133a-3p, miR-326, miR-331-3p, miR-369-3p, miR-328-3p, miR-26a-3p, miR-139-3p, miR-493-3p, miR-664a-5p, miR-323b-3pmiR-1307-3p and miR-423-3p) and 3 were up-regulated (miR-101-3p, miR-146a-5p and miR-144-3p). Hierarchical clustering using differentially expressed miRNAs clearly distinguished patients according to their lymph node status. We did not find any difference in the miRNA expression profile between plasma samples associated with macrometastasis or micrometastasis. The expression of 9 miRNAs was validated by qPCR. Moreover, gene ontology analysis showed a significant enrichment of biological processes associated with the regulation of the epithelial mesenchymal transition, cell proliferation and transcriptional regulation. Conclusions: Our results indicated the potential role of several circulating miRNAs as surrogate markers of lymph node metastases in early breast cancer patients. Further validation in a larger cohort of patients will be necessary to confirm our results.

show abstract

“…With the development of abundant open data resources, it is convenient and effective for researchers to screen cancer-related therapeutic targets (7). Through an analysis of The Cancer Genome Atlas (TCGA) database, the present study identified tripartite motif-containing protein 59 (TRIM59) as a novel lung cancer-related candidate target.…”

Section: Introductionmentioning

confidence: 98%

TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC

et al. 2019

View full text Add to dashboard Cite

As a member of the tripartite motif family, tripartite motif-containing protein 59 (TRIM59) serves as an E3 ubiquitin ligase in various cellular processes, including intracellular signaling, development, apoptosis, protein quality control, innate immunity, autophagy and carcinogenesis. The present study aimed to investigate the expression and prognostic value of TRIM59 in patients with non-small cell lung cancer (NSCLC). Expression of TRIM59 in patients with NSCLC was measured by immunohistochemistry in tissue microarrays. Datasets from The Cancer Genome Atlas (TCGA) were used to further verify the expression level of TRIM59 in NSCLC, lung adenocarcinoma and lung squamous cell carcinoma (LUSC). The prognostic value of TRIM59 in NSCLC was also analyzed. Immunohistochemistry revealed that TRIM59 was primarily located in the cytoplasm of tumor cells. Analysis of TCGA datasets revealed that TRIM59 was more highly expressed in tumor tissues than in normal tissues (P<0.0001). Furthermore, the TRIM59 expression level was associated with tumor differentiation (P=0.012), while no association was observed between TRIM59 expression and any other clinicopathological parameters. However, the average overall survival rate of patients with NSCLC in the high TRIM59 expression group was significantly lower than that in the low expression group (P=0.014), especially in patients with LUSC (P=0.016) and patients with poor differentiation (P=0.033). The multivariate analysis indicated that high TRIM59 expression is an independent prognostic factor in patients with NSCLC (P=0.018) and was associated with poor prognosis in patients with NSCLC. Therefore, TRIM59 may serve as a novel molecular biomarker to predict the prognosis of patients with NSCLC.

show abstract

Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics

Cited by 30 publications

References 49 publications

Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer

Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer

Circulating microRNAs in Early Breast Cancer Patients and Its Association With Lymph Node Metastases

TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC

Contact Info

Product

Resources

About